Aldesleukin is under clinical development by Iltoo Pharma and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Aldesleukin’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 08 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Aldesleukin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Aldesleukin overview

ILT-101 is under development for the treatment of autoimmune and inflammatory diseases including type I diabetes, acute respiratory distress syndrome due to Coronavirus disease 2019 (COVID-19), relapsing remitting multiple sclerosis, recurrent miscarriage, systemic lupus erythematosus, allergic rhino-conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet disease, Wegener granulomatosis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjogren, systemic sclerosis, idiopathic thrombocytopenic purpur, bipolar disorder and amyotrophic lateral sclerosis. It is administered by subcutaneous route and formulated as powder for solution as an injection. The drug candidate is a human recombinant Interleukin-2 which acts by targeting interleukin receptor2. It was also under development for Takayasu disease.

Quick View Aldesleukin LOA Data

Report Segments
  • Innovator
Drug Name
  • Aldesleukin
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
  • Women’s Health
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.